Papers
2
Total Citations
12
H-Index
2
About
Jisheng Qin is a biomedical engineer whose work sits at the intersection of high-throughput automation, infectious disease diagnostics, and regenerative medicine. In a landmark 2022 study, Qin developed an automatic system for the high-throughput, high-sensitivity diagnosis of SARS-CoV-2, a critical contribution during the pandemic that has already garnered 10 citations for its potential to scale testing capacity without sacrificing accuracy. More recently, Qin has pushed the boundaries of somatic cell reprogramming, introducing a robotic-based, spatial-restricting structured flow method to select monoclonal cell lineages from induced pluripotent stem cells (iPSCs). This innovation addresses a persistent bottleneck in regenerative medicine: the heterogeneity and lineage manipulation that can compromise the safety and efficacy of iPSC-derived therapies. By automating the isolation of uniform, high-quality clones, Qin’s approach promises to accelerate personalized disease modeling and cell-based treatments. With a growing body of work that bridges clinical diagnostics and stem cell engineering, Jisheng Qin is emerging as a versatile researcher whose automated platforms are poised to make both pandemic response and regenerative therapies more reliable and scalable.
Research Focus
Key Achievements
Top Papers
- 1
- 2